Aug 2026
Drug repurposing-guided discovery of novel methyl quinoline-6-carboxylate RIPK3 inhibitors through structural optimization of Gefitinib.
Overall, this study identifies Gefitinib as a novel RIPK3-targeting scaffold and demonstrates that structure-guided optimization of an EGFR inhibitor can yield potent and selective RIPK3-directed anti-necroptotic agents.
Ying Shi, Guojing Tao, Rui-Xia Zhang et al.
· European journal of medicina... · 0 citations